Changes in tumor markers, coagulation function and serum VEGF in patients with ovarian cancer and benign ovarian disease

被引:4
|
作者
Wang, Jiaying [1 ]
Zhu, Miaohua [1 ]
Zhou, Xiaoming [1 ]
Wang, Tingting [1 ]
Zhang, Jing [1 ]
机构
[1] Ningbo Univ, Dept Obstet & Gynecol, Affiliated Hosp, Med Sch, 247 Renmin Rd, Ningbo 315000, Zhejiang, Peoples R China
来源
JOURNAL OF BUON | 2020年 / 25卷 / 05期
基金
浙江省自然科学基金;
关键词
ovarian cancer; tumor markers; coagulation function; VEGF; EXPRESSION; CHEMOTHERAPY;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the changes in tumor markers (TMs), coagulation function and vascular endothelial growth factor (VEGF) in patients with ovarian cancer (OC) and benign ovarian disease (BOD). Methods: A total of 68 OC patients admitted to and treated in our hospital were selected (OC group), and another 68 BOD patients in the same time period were enrolled (BOD group). The variations in TMs, coagulation function and VEGF in OC and BOD patients were explored by analyzing the TMs, coagulation function and expression levels of serum VEGF and D-dimer in OC group and BOD group as well as the differences in TMs and coagulation function in patients in different stages. Results: The values of TMs such as cancer antigen 125 (CA125), carbohydrate antigen 19.9 (CA19.9) and human epididymis protein 4 (HE4) in OC group were remarkably higher than those in BOD group, with significant differences (p<0.05). The values of those TMs were relatively low in the patients in stage I-II but relatively high in the patients in stage III-IV, and the patients in stage I-II had evidently lower values of those TMs than those in stage III-IV (p 0.05). The coagulation function was similar in both groups (p 0.05). The levels of coagulation function indexes [prothrombin time (PT), thrombin time (TT) and activated partial thromboplastin time (APTT)] in the patients in stage I-II were comparable to those in stage III-IV, showing no differences (p 0.05), but the serum FIB level was markedly higher in the patients in stage III-IV than that in in stage I-II (p<0.05). The expression level of serum VEGF was increased distinctly in OC group compared with that in BOD group [(378.15 +/- 94.45) pg/mL vs. (164.02 +/- 67.38) pg/mL, p<0.05]. Moreover, OC group manifested obviously elevated expression level of serum D-dimer in comparison with BOD group [(4.58 +/- 1.48) mu g/mL vs. (0.67 +/- 0.12) mu g/mL, p<0.05]. Conclusions: TMs, coagulation function indexes and serum VEGF and D-dimer are highly expressed in OC patients, and the combined detection of TMs, coagulation function and serum VEGF can serve as an important method of diagnosing OC.
引用
收藏
页码:2287 / 2292
页数:6
相关论文
共 50 条
  • [1] SERUM MARKERS AND CYTOKINES IN PATIENTS WITH OVARIAN CANCER, ENDOMETRIOSIS OR OTHER BENIGN OVARIAN TUMOURS
    Nowak, Marek
    Misiek, Marcin
    Janas, Lukasz
    Piwowarczyk, Iwona
    Soja, Malwina
    Masternak, Martyna
    Glowacka, Ewa
    Kielbik, Michal
    Szulc-Kielbik, Izabela
    Klink, Magdalena
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A60 - A60
  • [2] Serum sFas, Leptin, and VEGF in Patients with Ovarian Cancer and Benign Tumors
    M. M. Vysotskii
    M. A. Digaeva
    N. E. Kushlinskii
    S. G. Abbasova
    K. P. Laktionov
    V. D. Ermilova
    K. A. Bakhoeva
    Yu. V. Kryuk
    I. B. Manukhin
    [J]. Bulletin of Experimental Biology and Medicine, 2009, 148 : 810 - 814
  • [3] Serum sFas, Leptin, and VEGF in Patients with Ovarian Cancer and Benign Tumors
    Vysotskii, M. M.
    Digaeva, M. A.
    Kushlinskii, N. E.
    Abbasova, S. G.
    Laktionov, K. P.
    Ermilova, V. D.
    Bakhoeva, K. A.
    Kryuk, Yu. V.
    Manukhin, I. B.
    [J]. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2009, 148 (05) : 810 - 814
  • [4] COORDINATE ELEVATION OF SERUM MARKERS IN OVARIAN-CANCER BUT NOT IN BENIGN DISEASE
    BAST, RC
    KNAUF, S
    EPENETOS, A
    DHOKIA, B
    DALY, L
    TANNER, M
    SOPER, J
    CREASMAN, W
    GALL, S
    KNAPP, RC
    ZURAWSKI, VR
    SCHLOM, J
    KUFE, DW
    RITTS, RE
    [J]. CANCER, 1991, 68 (08) : 1758 - 1763
  • [5] COORDINATE ELEVATION OF SERUM MARKERS IN OVARIAN-CANCER BUT NOT IN BENIGN DISEASE
    BAST, RC
    KNAUF, S
    EPENETOS, A
    TANNER, M
    KLUG, T
    SOPER, J
    CREASMAN, W
    GALL, S
    KNAPP, RC
    ZURAWSKI, V
    SCHLOM, J
    KUFE, D
    RITTS, RE
    [J]. HYBRIDOMA, 1987, 6 (02): : 235 - 235
  • [6] COORDINATE ELEVATION OF SERUM MARKERS IN OVARIAN-CANCER BUT NOT IN BENIGN DISEASE
    BAST, RC
    KNAUF, S
    EPENETOS, AA
    TANNER, M
    KLUG, T
    SOPER, J
    CREASMAN, W
    GALL, S
    KNAPP, RC
    ZURAWSKI, V
    SCHLOM, J
    KUFE, D
    RITTS, RE
    [J]. BRITISH JOURNAL OF CANCER, 1987, 56 (04) : 509 - 510
  • [7] Ovarian tumor markers of presumed benign ovarian tumors
    Lahlou, N.
    Brun, J. -L.
    [J]. JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION, 2013, 42 (08): : 752 - 759
  • [8] SERUM CHEMOKINE LEVELS IN PATIENTS WITH OVARIAN CANCER OR BENIGN OVARIAN CYSTS
    Nowak, M.
    Glowacka, E.
    Janas, L.
    Wilczynski, J. R.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1458 - 1458
  • [9] Multiplex serum tumor markers for the prediction of early relapse in ovarian cancer patients
    Steffiensen, Karina D.
    Waldstrom, Marianne
    Visintin, Irene
    Brandslund, Ivan
    Jakobsen, Anders
    Mor, Gil
    [J]. REPRODUCTIVE SCIENCES, 2008, 15 (02) : 301A - 301A
  • [10] Tumor Markers in ovarian cancer
    Duffy, Michael J.
    Esteva, Francisco J.
    Harbeck, Nadia
    Hayes, Daniel F.
    Molina, Rafael
    [J]. ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2014, 48 (01): : 88 - 106